KSQ Therapeutics

Mission Therapeutics is looking to protein modulation to treat a variety of diseases associated with malfunctioning mitochondria and has raised just over £25m ($32m) to advance its candidates, includ

Exelixis has licensed the rights to ISM3091, a novel cancer treatment from AI-based drug discovery company Insilico Medicine , as it looks to find new growth drivers beyond its blockbuster Cabometyx

Roche Holding AG is keeping its business development teams busy but any opportunities will have to tick several boxes before the Swiss major proceeds with a deal. That is the stance being taken by CE

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sangamo Partners In Neurology With Lill